Dyne Therapeutics

NSQ:DYN · US26818M1080

BiotechnologySmall

360° View

Value18

Price/Sales9

Price/Earnings54

Price/Book19

Dividend Yield—

Growth21

Revenue Growth—

Profit Growth6

Capital Growth52

TSR 52w34

Safety62

Leverage20

Liquidity48

Refinancing91

Combined18

Sentiment75

Analyst Opinions19

Pro Holdings100

Opinion Changes50

Market Pulse75

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2017

Employees241

Websitedyne-tx.com

ISINUS26818M1080

Last UpdateApr 2, 2026

Index & Theme

GeneticsNeurologyChronic DiseasesCentral Nervous SystemOrthopaedicsNeuroscienceGenetic DisorderBiotechnologyHealth CareMedicalPharmaceutical

Description

Dyne Therapeutics, Inc. operates as a clinical-stage neuromuscular disease company. The company's proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue, and the cent…

Analysis

Dyne Therapeutics's 360° View rank of 34 places it below its peer average — better than 34% of its true peers.

It's lagging on growth (21) and expensive versus peers (18). On safety it is financially sound (62), and the market shows favorable sentiment (75). Taken together, its Combined rank of 18 reads as among the weakest overall.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Dyne Therapeutics with its peers

PepGen

NSQ:PEPG

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immunic

NAQ:IMUX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Monopar Therapeutics

NAQ:MNPR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immuneering

NMQ:IMRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Regenxbio

NSQ:RGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Acumen Pharmaceuticals

NSQ:ABOS

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →